G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia.
Apostolia Maria Tsimberidou,Eli Estey,Hagop M. Kantarjian,Michael J. Keating,Sherry Pierce,Guillermo Garcia-Manero +5 more
TL;DR: Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia and Granulocyte colonies stimulated by Tournais-Bouchut-Boyaval administration are associated with cerebrospinal hemorrhage.
Journal ArticleDOI
Clinical Development of MGCD0103, An Isotype-Selective HDAC Inhibitor: Pericarditis/Pericardial Effusion in the Context of Overall Safety and Efficacy.
Robert E. Martell,Guillermo Garcia-Manero,Anas Younes,Michael S. Ewer,Iyad N. Daher,Michel Drouin,Wendy Hunt,Karine Lortie,Jennifer Wilhelm,Jeffrey M. Besterman +9 more
TL;DR: Based on the literature and Investigator-driven preliminary reviews, rates of pericardial findings can vary from 3% to approximately 40% in patients with advanced cancers who may have received multiple previous anticancer therapies, and no chemotherapeutic class appears to be directly related to causing more severe pericARDial effusions.
Journal ArticleDOI
Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelodysplastic Syndromes
Guillermo Garcia-Manero,Steven D. Gore,Suman Kambhampati,Bart L. Scott,Ayalew Tefferi,Christopher R. Cogle,William Jeffery Edenfield,Joel Hetzer,Keshava Kumar,Barry S. Skikne +9 more
TL;DR: This ongoing, multicenter, phase 1 study enrolled pts with lower-risk MDS who were RBC transfusion dependent (TD) and/or thrombocytopenic and preliminary evidence suggests that extending oral azacitidine dosing to 14d or 21d of the 28d cycle may enhance pharmacodynamic and epigenetic activity.
Journal ArticleDOI
Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.
Hong Fang,Mariko Yabe,Xiaohui Zhang,Young L. Kim,Xiaojun Wu,Peng Wei,Sunyi Chi,Lan Zheng,Guillermo Garcia-Manero,Lina Shao,Ji Yuan,Yulei Shen,Gang Zheng,Guiling Tang,Wei Wang,Sanam Loghavi,Qi Shen,Yongzhong Yuan,Rong He,Dong Chen,L. Jeffrey Medeiros,Shimin Hu +21 more
TL;DR: In this paper, the authors compared the clinicopathologic features of 107 patients with myeloid neoplasms harboring t(6;9)/DEK-NUP214: 33 MDS and 74 AML.
Journal ArticleDOI
Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML
Naval Daver,Guillermo Garcia-Manero,Sreyashi Basu,Jorge E. Cortes,Farhad Ravandi,Elias J. Jabbour,Rita Assi,Mark Brandt,Sherry Pierce,Tauna Gordon,Naveen Pemmaraju,Michael Andreeff,Jing Ning,Steven M. Kornblau,Tapan M. Kadia,Wilmer Flores,Jairo Matthews,Courtney D. DiNardo,Gautam Borthakur,Marina Konopleva,James P. Allison,Padmanee Sharma,Hagop M. Kantarjian +22 more
TL;DR: The response rate did not differ by age ≤65 versus >65 years, was higher in pts with diploid cytogenetics, pts without prior HMA therapy, and pts with ASXL1 mutations, and compares favorably to historical median OS with AZA-based salvage protocols in similar pts at MDACC.